| 50.19 -0.89 (-1.74%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.65 | 1-year : | 74.35 |
| Resists | First : | 54.5 | Second : | 63.65 |
| Pivot price | 49.72  |
|||
| Supports | First : | 48.97 | Second : | 45.56 |
| MAs | MA(5) : | 51.13 |
MA(20) : | 49.26 |
| MA(100) : | 46.07 |
MA(250) : | 38.02 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 61 |
D(3) : | 64.9 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 54.5 | Low : | 24.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRCT ] has closed below upper band by 45.2%. Bollinger Bands are 54.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 51.62 - 52.04 | 52.04 - 52.32 |
| Low: | 47.66 - 48.11 | 48.11 - 48.41 |
| Close: | 49.59 - 50.3 | 50.3 - 50.78 |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Fri, 19 Apr 2024
PROCEPT BioRobotics Announces Board Member Transition - TipRanks.com - TipRanks
Thu, 18 Apr 2024
Allspring Global Investments Holdings LLC Sells 761,589 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) - MarketBeat
Mon, 15 Apr 2024
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 3.5% - MarketBeat
Fri, 05 Apr 2024
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) - Simply Wall St
Thu, 04 Apr 2024
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas - GlobeNewswire
Fri, 01 Mar 2024
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These ... - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 51 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 91.6 (%) |
| Shares Short | 4,650 (K) |
| Shares Short P.Month | 4,520 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.53 |
| Profit Margin | -77.8 % |
| Operating Margin | -67.9 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 83.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.67 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -108 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -22.41 |
| PEG Ratio | -2.5 |
| Price to Book value | 9.07 |
| Price to Sales | 18.78 |
| Price to Cash Flow | -23.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|